|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
| ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 91
References
Abrams, J., R. Erwin, G. Fyfe, R. L. Schilsky, and R. Temple. 2009. Data submission
standards and evidence requirements. Presented at the Conference on Clinical Cancer
Research, Panel 1. Engelberg Center for Health Care Reform, Brookings Institution,
Washington, DC.
ACS CAN (American Cancer Society Cancer Action Network). 2009. Barriers to provider
participation in clinical cancer trials: Potential policy solutions. Washington, DC:
American Cancer Society Cancer Action Network.
C-Change and the Coalition for Cancer Cooperative Groups. 2006. Enhancing cancer
treatment through improved understanding of the critical components, economics, and
barriers of cancer clinical trials. Washington, DC: C-Change; Philadelphia, PA: Coalition
of Cancer Cooperative Groups.
Cheng, S. K., M. Dietrich, S. Finnigan, A. Sandler, J. Crites, L. Ferranti, A. Wu, and D. Dilts.
2009. A sense of urgency: Evaluating the link between clinical trial development time
and the accrual performance of CTEP-sponsored studies. Journal of Clinical Oncology
200ASCO Annual Meeting Proceedings 27(18 Suppl.):CRA6509.
CTEP (Cancer Therapy Evaluation Program). 2011. CTEP intellectual property option to
collaborator. Federal Register 76(48):13404-13410.
Federal Register. 2011. Human Subjects Research Protections: Enhancing Protections for Research
Subjects and Reducing Burden, Delay, and Ambiguity for Investigators. Volume 76,
Number 143. http://www.gpo.gov/fdsys/pkg/FR-2011-07-26/html/2011-18792.htm
(accessed July 27, 2011).
Flaherty, K. T., I. Puzanov, K. B. Kim, A. Riba, G. A. McArthur, J. A. Sosman, P. J.
O’Dwyer, R. L. Lee, J. F. Grippo, K. Nolop, and P. B. Chapman. 2010. Inhibition of
mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine
26;363(9):809-819.
Gianni, L. 2009. Anthracyclines and early breast cancer: The end of an era? Journal of Clinical
Oncology 27(8):1155-1157.
91
OCR for page 92
92 IMPLEMENTING A NATIONAL CANCER CLINICAL TRIALS SYSTEM
Hautala, J. 2010. Cooperative Group Financial, Organizational and Management Analysis.
Presentation to the NCI Clinical Trials and Translational Research Advisory Committee,
September 21. http://deainfo.nci.nih.gov/advisory/ctac/0910/presentations/Hautala.
pdf (accessed April 21, 2011).
IOM (Institute of Medicine). 2010. A national cancer clinical trials system for the 21st century:
Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National
Academies Press.
Jones, S., F. A. Holmes , J. O’Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E.
Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, W. J. Hyman, D. A. Richards, R. G.
Mennel, K. A. Boehm, W. G. Meyer, L. Asmar, D. Mackey, S. Riedel, H. Muss, and
M. A. Savin. 2009. Docetaxel with cyclophosphamide is associated with an overall
survival benefit compared to doxorubicin and cyclophosphamide: 7-year follow-up
of US Oncology Research Trial 9735. Journal of Clinical Oncology 27(8):1177-1183.
Kanarek, N. F., H. L. Tsai, S. Metzger-Gaud, D. Damron, A. Guseynova, J. F. Klamerus, and
C. M. Rudin. 2010. Geographic proximity and racial disparities in cancer clinical trial
participation. Journal of the National Comprehensive Cancer Network 8(12):1343-1351.
Klabunde, C. N., N. L. Keating, A. L. Potosky, A. Ambs, Y. He, M. C. Hornbrook, and
P. A. Ganz. 2011. A population-based assessment of specialty physician involvement in
cancer clinical trials. Journal of the National Cancer Institute 103(5):384-397.
Klamerus, J. F., S. S. Bruinooge, X. Ye, M. L. Klamerus, D. Damron, D. Lansey, J. C.
Lowery, L. A. Diaz, Jr., J. G. Ford, N. Kanarek, and C. M. Rudin. 2010. The impact
of insurance on access to cancer clinical trials at a comprehensive cancer center. Clinical
Cancer Research 16(24):5997-6003.
Korn, E. L., B. Freidlin, M. Mooney, and J. S. Abrams. 2010. Accrual experience of National
Cancer Institute Cooperative Group Phase III trials activated from 2000 to 2007.
Journal of Clinical Oncology 28(35):5197-5201.
Kwak, E. L., Y. J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S. H. Ou, B. J.
Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W. H. Kim, T. J. Lynch, P. Fidias,
H. Stubbs, J. A. Engelman, L. V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson,
G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber,
K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, and A. J. Iafrate. 2010. Anaplastic
lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of
Medicine 363(18):1693-1703.
Moss, A. J., C. W. Francis, and D. Ryan. 2011. Collaborative clinical trials. New England
Journal of Medicine 364(9):789-791.
NCI (National Cancer Institute). 2005. Report of the clinical trials working group of the
National Cancer Advisory Board: Restructuring the National Cancer Clinical Trials
Enterprise. Bethesda, MD: National Cancer Institute.
———. 2010. Report of the operational efficiency working group of the Clinical Trials and
Translational Research Advisory Committee: Compressing the timeline for cancer clinical
trial activation. Bethesda, MD: National Cancer Institute.
Perry, M. C., R. L. Comis, and R. L. Schilsky. 2008. Introduction: Contributions of the
cooperative groups. Seminars in Oncology 35(5):459.
Research!America. 2010. Research enterprise survey. http://www.researchamerica.org/uploads/
ResearchEnterprisePoll.pdf (accessed April 20, 2010).
OCR for page 93
93
REFERENCES
Schroen, A. T., G. R. Petroni, H. Wang, B. Djulbegovis, C. L., Slingluff, X. F. Wang, R. Gray,
D. J. Sargent, W. Cronin, and J. Benedetti. 2009. Challenges to accrual predictions to
Phase III cancer clinical trials: A survey of study chairs and lead statisticians of 248 NCI-
sponsored trials. Journal of Clinical Oncology 27:15s (suppl; abstr 6562).
Sood, A., K. Prasad, L. Chhatwani, E. Shinozaki, S. Cha, L. Loehrer, and D. Wahner-Roedler.
2009. Patients’ attitudes and preferences about participation and recruitment strategies
in clinical trials. Mayo Clinical Proceedings 84(3):243-247.
Stunkel, L., M. Benson, L. McLellan, N. Sinaii, Bedarida G., E. Emanuel, and C. Grady.
2010. Comprehension and informed consent: Assessing the effect of a short consent
form. IRB Ethics and Human Research 32(4):1-9.
Su, S. C., N. Kanarek, M. G. Fox, A. Guseynova, S. Crow, and S. Piantadosi. 2010. Spatial
analyses identify the geographic source of patients at a National Cancer Institute
comprehensive cancer center. Clinical Cancer Research 16(3):1065-1072.
OCR for page 94
